MedTrace Logo

A Retrospective Study on Drug Induced Liver Injury in China

NCT02407964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2016-10-26

No results posted yet for this study

Summary

This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences among all the hospitalized patient, among patients in department of hepatic diseases, digestive diseases, oncology, hematology etc., individually; 2) epidemiologic characteristics of drug-induced liver injury, including suspected medications, clinical types, histological characteristics, severity and outcomes.

Conditions

  • Drug-Induced Liver Injury

Sponsors & Collaborators

  • Unimed Scientific Inc.

    collaborator INDUSTRY

  • Drug Induced Liver Disease Study Group

    lead OTHER

Principal Investigators

  • Yimin Mao, MD · RenJi Hospital

  • Chengwei Chen, MD · No. 85 Hospital of PLA

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-05-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02407964 on ClinicalTrials.gov